ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2193

Prevalence of Raynaud’s Phenomenon and Nailfold Capillaroscopic Abnormalities in Fabry’s Disease: A Cross-Sectional Study

Samuel Deshayes1, Roland Jaussaud2, Bernard Imbert3, Olivier Lidove4, Jean-Jacques Parienti5, Nathalie Triclin6, Laurent Auboire7 and Boris Bienvenu1, 1Médecine interne, CHU Côte de Nacre, CAEN, France, 2Médecine interne, maladies infectieuses, immunologie clinique, CHU de Reims, REIMS, France, 3CHU, Grenoble, Grenoble, France, 4Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, 5Biostatistiques, CHU Côte de Nacre, CAEN, France, 6Association des Patients de la Maladie de Fabry, VENDRESSE, France, 7Inserm U930, UMR Imagerie et Cerveau, TOURS, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Raynaud's phenomenon and capillaroscopy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Fabry’s disease (FD) is a lysosomal disorder leading to progressive systemic involvement, including neurologic and vascular. We hypothesize that the microangiopathy observed in FD could be documented, including at an early stage, by using nailfold capillaroscopy and assessing the presence of Raynaud’s phenomenon (RP). The objective of this study was to measure the prevalence of RP and nailfold capillaroscopic abnormalities in FD.

Methods: This cross-sectional study included a standardized questionnaire and a nailfold capillaroscopy assessing previous reported patterns in FD (dystrophic and giant capillaries, avascular fields, irregular architecture, dilatation and density of capillaries, hemorrhage), and was conducted on 32 Fabry patients and 39 controls. Two independent blinded reviewers carried out the analysis of capillaroscopic photographs.

Results:

Table 1 : Demographic and clinical characteristics of Fabry patients and controls

Fabry patients Control group p value
n 32 39
Age, mean ± SD 45,5 ± 13,8 48,2 ± 11,5 0.38
Sex-ratio (males/females) 0,46 (10/22) 1,6 (24/15) 0.02
Smoking, n (%) 1 (3) 4 (10) 0.37

Cannabis, n (%)

0 (0) 0 (0) 1
Hypertension, n (%) 8 (25) 4 (10) 0.1
Hyperlipidemia, n (%) 4 (13) 4 (10) 1
Diabetes, n (%) 1 (3) 3 (8) 0.63
Pain in the extremities, n (%) 28 (88) 0 (0) <0.001
Enzyme replacement therapy, n (%) 25 (78) 0 (0) <0.001

Table 2 : Characteristics of patients suffering from Raynaud’s phenomenon (RP)

Fabry patients Control group p value
Males with RP, n (%) 5/10 (50) 0/24 (0) <0.001
Females with RP, n (%) 7/22 (32) 2/15 (13) 0.27
Total with RP, n (%) 12/32 (38) 2/39 (5) <0.001

Patients with FD and RP all suffered from pain in the extremities, whereas none in the control group did (p = 0.011). RP was concomitant or prior to the occurrence of pain in the extremities in 42% of Fabry patients. Significantly more ramified capillaries were observed in Fabry patients (12/32, 38%) than in controls (5/39, 15%, p = 0.016). No other statistically significant difference was observed by nailfold capillaroscopy.

Conclusion: This study is, to the best of our knowledge, the largest one assessing nailfold capillaroscopy and the presence of RP in FD. RP was highly prevalent in our series of Fabry patients (38%) and involved 50% of males. FD should thus be considered as a cause of secondary RP. RP was concomitant or prior to the occurrence of pain in the extremities in almost 50% of Fabry patients. It could be, at least in part, a causal factor of these pains. Secondary RP should lead to a screening for FD, especially in men. By extension, in high-risk populations (i.e. hypertrophic cardiomyopathy, dialysis patients, stroke in young people), the presence of ramified capillaries and RP should also be assessed.


Disclosure:

S. Deshayes,

Genzyme Corporation,

9;

R. Jaussaud,

SHIRE,

6,

Genzyme Corporation,

6;

B. Imbert,
None;

O. Lidove,

SHIRE,

6,

Genzyme Corporation,

6;

J. J. Parienti,
None;

N. Triclin,
None;

L. Auboire,
None;

B. Bienvenu,

Genzyme Corporation,

6,

Shire,

6.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-raynauds-phenomenon-and-nailfold-capillaroscopic-abnormalities-in-fabrys-disease-a-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology